The markers that actually move risk
Not all cholesterol numbers are equal. Apolipoprotein B (ApoB) counts the atherogenic particles that actually initiate and sustain plaque formation, and international lipid guidelines increasingly place it at the centre of risk assessment. Lipoprotein(a) is largely genetically determined and should be measured at least once in a lifetime. Full lipid profiles, HbA1c and structured blood pressure assessment complete the picture.
We measure these markers under controlled conditions and interpret them against your history, medication, family history and lifestyle – never as isolated numbers on a printout.
From scattered values to a personal risk picture
Risk stratification requires medical expertise, not an automated score. The physician combines your biomarker results with age, family history, blood pressure, glycemic markers and relevant examination findings into a coherent cardiovascular risk assessment – and translates what that means for you personally, including what it does not mean.
Where your risk profile warrants it, further examination follows a clinical question: a resting ECG where appropriate, and advanced imaging such as coronary calcium scoring or CT angiography when the answer would change what we do. Advanced imaging is arranged by personal agreement and billed separately.
Managing risk is a continuous task
Cardiovascular prevention succeeds over years, not appointments. In our longitudinal programs your markers are re-measured on a defined cadence, trends are analysed at scheduled consultations, and medication use is discussed where clinically appropriate – openly with you, and, with your consent, shared with your own physicians where relevant.
Between consultations, wearable data – heart-rate variability, sleep, activity – provides continuous context in your clinical record. It supports, but never replaces, clinical measurement.
